Search Results

With an eye toward advancing a novel antibody-drug conjugate for gastrointestinal cancers, ArriVent is the latest biopharma player to ink a deal with a Chinese biotech.

Ascentage is looking to use the IPO proceeds to advance its Phase III candidates for chronic or small lymphocytic leukemia and for certain types of chronic myeloid leukemia.

Indapta Therapeutics, Inc. announced that CEO Mark Frohlich, MD, will be giving a plenary talk today titled, “g-NK cells for the treatment of cancer and autoimmune disease” at the New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference.

Kyverna Therapeutics, Inc. (Kyverna) announced today the publication in Proceedings of the National Academy of Sciences (PNAS)1 of a report describing the first use of KYV-101, a fully human anti-CD19 chimeric antigen receptor (CAR) T-cell product candidate, in a 69-year-old patient suffering from treatment-refractory stiff-person syndrome (SPS) as part of a named-patient use in Germany for critically ill individuals who fail conventional therapies.

The Pontifical Academy of Sciences is proud to announce that Dr. Christina Rahm will be honored at its prestigious summit on May 29, 2024, at the Vatican. A distinguished scientist, entrepreneur, and philanthropist, Dr. Rahm has been recognized for her significant contributions to healthcare innovation and her unwavering commitment to improving global health.

Astria Therapeutics, Inc. today announced that it will present two posters at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Congress in Valencia, Spain on June 1, 2024.

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”) announces the presentation of data from the Company’s PARADIGM Phase 2b study of PrimeC during an Emerging Science session (equivalent to Late Breaker) at the American Academy of Neurology Annual Meeting, which validates the previously announced topline data.

BlossomHill Therapeutics today announced Jingrong Jean Cui, Ph.D., Co-Founder, President and Chief Executive Officer of BlossomHill Therapeutics, has been elected to the National Academy of Engineering (NAE).